Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus FOLFOX4 or XELOX2 as first-line therapy in colorectal cancer
2010-022091-31Phase 2Completed
- Sponsor
- GOIM
- Start
- Jun 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab, oxaliplatin, capecitabine, fluorouracil and levoleucovorin in colorectal cancer (CRC) and colon adenocarcinoma (2 arms), sponsored by GOIM. Primary endpoint: Objective response rate with XELOX2 + bevacizumab. Started Jun 2011; status: completed.
02
Drugs
bevacizumaboxaliplatincapecitabinefluorouracillevoleucovorin
03
Conditions
colorectal cancer (CRC)colon adenocarcinoma
Beyond the preview
Go deeper on 2010-022091-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022091-31.